Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

The study explored erenumab's safety and efficacy in chronic migraine patients. Researchers conducted a phase 2, randomized, double-blind trial across 69 centers in North America and Europe. Participants were adults aged 18-65, experiencing 15 or more headache days monthly. They received either subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg every four weeks for twelve weeks. Results indicated that both erenumab doses significantly reduced monthly migraine days compared to placebo. Erenumab 70 mg and 140 mg reduced migraine days by 6.6 days, while placebo reduced them by 4.2 days. Adverse events occurred in 39% of placebo patients and 44% and 47% of erenumab patients, respectively. Serious adverse events were rare and did not lead to discontinuation. Overall, the findings suggest erenumab may be a viable preventive treatment for chronic migraine. Further studies are essential to assess long-term effects and real-world applicability. Clinical relevance: This research indicates that erenumab could provide effective preventive treatment for chronic migraine patients.